


Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. - 117. (cancelled)

118. (new) A pharmaceutical or cosmetic composition comprising at least one of a pharmaceutically or cosmetically acceptable carrier and a pharmaceutically or cosmetically acceptable adjuvant and at least one active ingredient selected from compounds of formula C4, including pharmaceutically acceptable salts thereof:



C4

wherein

- X1, X2, X3 and X4 represent identical or different carbon units;
- Y1 represents NH and Y2 and Y3 represent identical or different carbon units;
- R1 and R2 symbolize a substitution pattern of a respective partial ring, wherein R1 represents one to four identical or different substituents and R2 represents two different substituents; R1 being selected from hydrogen, unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl, C₂- to C₁₂ alkenyl and C₂- to C₁₂ alkynyl, hydroxy, thiol, C₁-

to C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl, and unsubstituted or substituted imino; and R₂ being selected from hydrogen and unsubstituted or substituted methyl and ethyl groups.

119. (new) The composition of claim 118, wherein one R₂ is selected from hydrogen and methyl and the other R₂ is selected from substituted methyl and ethyl groups.

120. (new) The composition of claim 118, wherein one R₂ is methyl and the other R₂ is substituted methyl.

121. (new) The composition of claim 118, wherein R₁ is selected from hydrogen, and unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl.

122. (new) The composition of claim 119, wherein R₁ is selected from hydrogen, and unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl.

123. (new) The composition of claim 120, wherein R₁ is selected from hydrogen, and unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl.



P29679.A06





124. (new) The composition of claim 118, wherein the substituents R1 represent hydrogen.





125. (new) The composition of claim 119, wherein the substituents R1 represent hydrogen.





126. (new) The composition of claim 120, wherein the substituents R1 represent hydrogen.

127. (new) The composition of claim 118, wherein the composition comprises at least one active ingredient selected from compounds of the following formulae, including pharmaceutically acceptable salts thereof:


C4.002	
C4.005	

C4.007	 <chem>CCOC(=O)C1CCN(C1C2=CC=CC=C2C3=C(C)C=C4C(=C(C=C3)N=C4C5=CC=CC=C5)C6=CC=CC=C6)C7=CC=CC=C7</chem>
C4.008	 <chem>C1=CC=C(C=C1)C2=C(C)C=C3C(=C(C=C2)N=C3C4=CC=CC=C4)C5=CC=CC=C5C6=CC=CC=C6N7CCN(C7C8=CC=CC=C8)C9=CC=CC=N9</chem>
C4.009	 <chem>CC1=CC=C(C=C1)C2=C(C)C=C3C(=C(C=C2)N=C3C4=CC=CC=C4)C5=CC=CC=C5C6=CC=C(C=C6)FN7CCN(C7C8=CC=CC=C8)C9=CC=CC=C9</chem>
C4.010	 <chem>NC(=O)C1CCN(C1C2=CC=CC=C2C3=C(C)C=C4C(=C(C=C3)N=C4C5=CC=CC=C5)C6=CC=CC=C6)C7=CC=CC=C7</chem>


C4.011	 <p>Chemical structure of 2-methyl-3-(2-(pyridin-2-yl)pyrrolidin-1-yl)indole. It features an indole ring with a methyl group at position 2 and a 2-(pyridin-2-yl)pyrrolidin-1-yl group at position 3.</p>
C4.012	 <p>Chemical structure of 2-methyl-3-(2-(pyridin-2-yl)morpholin-4-yl)indole. It features an indole ring with a methyl group at position 2 and a 2-(pyridin-2-yl)morpholin-4-yl group at position 3.</p>
C4.013	 <p>Chemical structure of 2-methyl-3-(2-(pyridin-2-yl)piperidin-1-yl)indole. It features an indole ring with a methyl group at position 2 and a 2-(pyridin-2-yl)piperidin-1-yl group at position 3.</p>
C4.014	 <p>Chemical structure of 2-methyl-3-(2-(thiophen-2-yl)piperidin-1-yl)-N-(2-oxoethyl)indole. It features an indole ring with a methyl group at position 2 and a 2-(thiophen-2-yl)piperidin-1-yl group at position 3. The piperidine ring is substituted with a 2-oxoethyl group (NH-C(=O)-CH₂-NH₂).</p>

C4.015	 <p>Chemical structure of 1-methyl-2-(2-(2-(2-ethylcarbamoyl)azepan-1-yl)-5-thienyl)indole-3-carboxamide. The structure features an indole ring with a methyl group at position 1 and a 2-(2-(2-(2-ethylcarbamoyl)azepan-1-yl)-5-thienyl) group at position 2. The azepane ring is connected to the indole at position 2 and has a 2-ethylcarbamoyl group at position 1. The thienyl group is connected to the azepane at position 2 and has a 2-ethylcarbamoyl group at position 5.</p>
C4.016	 <p>Chemical structure of 1-methyl-2-(2-(2-(2-methoxyphenyl)pyrrolidin-1-yl)indol-3-yl)indole-3-carboxamide. The structure features an indole ring with a methyl group at position 1 and a 2-(2-(2-(2-methoxyphenyl)pyrrolidin-1-yl)indol-3-yl) group at position 2. The pyrrolidine ring is connected to the indole at position 2 and has a 2-methoxyphenyl group at position 1. The indol-3-yl group is connected to the pyrrolidine at position 2 and has a 2-methoxyphenyl group at position 3.</p>
C4.017	 <p>Chemical structure of 1-methyl-2-(2-(2-(2-thienyl)azepan-1-yl)indol-3-yl)indole-3-carboxamide. The structure features an indole ring with a methyl group at position 1 and a 2-(2-(2-(2-thienyl)azepan-1-yl)indol-3-yl) group at position 2. The azepane ring is connected to the indole at position 2 and has a 2-thienyl group at position 1. The indol-3-yl group is connected to the azepane at position 2 and has a 2-thienyl group at position 3.</p>
C4.018	 <p>Chemical structure of 1-methyl-2-(2-(2-(2-thienyl)morpholin-1-yl)indol-3-yl)indole-3-carboxamide. The structure features an indole ring with a methyl group at position 1 and a 2-(2-(2-(2-thienyl)morpholin-1-yl)indol-3-yl) group at position 2. The morpholine ring is connected to the indole at position 2 and has a 2-thienyl group at position 1. The indol-3-yl group is connected to the morpholine at position 2 and has a 2-thienyl group at position 3.</p>

C4.019



128. (new) The composition of claim 118, wherein the composition comprises at least a compound of the following formula, including a pharmaceutically acceptable salt thereof:



129. (new) A method of inhibiting an activity of at least one enzyme selected from alanyl aminopeptidases, dipeptidyl peptidase and analogous enzymes in a subject in need thereof, wherein the method comprises administering to the subject the composition of claim 118 in an amount sufficient for inhibiting the activity of the at least one enzyme.

130. (new) A method of inhibiting an activity of at least one enzyme selected from alanyl aminopeptidases, dipeptidyl peptidase and analogous enzymes in a subject in need thereof, wherein

the method comprises administering to the subject the composition of claim 128 in an amount sufficient for inhibiting the activity of the at least one enzyme.

131. (new) A method of preventing or treating at least one condition selected from multiple sclerosis, Morbus Crohn, Colitis ulcerosa, rheumatoid arthritis, diabetes type I, autoimmune thyroid gland diseases, Morbus Wegener, systemic Lupus erythematosus visceralis and other autoimmune diseases; inflammatory diseases; allergic asthma bronchiale, allergic rhinitis, food allergy, atopic eczema, contact dermatitis, urticaria, angioedema and other allergic diseases; rejection of allogenic or xenogenic transplanted organs, tissues and cells such as, e.g. kidney, heart, liver, pancreas, skin or stem cell transplants; graft-versus-host diseases; skin and mucosa diseases; dermatological diseases associated with a hyperproliferation and changed differentiation states of fibroblasts; acute neuronal diseases, in particular ischemia-caused cerebral damages after an ischemic or hemorrhagic stroke, cranio-cerebral trauma, cardiac arrest, myocardial infarction or as a consequence of heart surgery; chronic neuronal diseases, in particular Alzheimer's disease, Pick's disease, Progressive Supranuclear Palsy, cortical degeneration, frontotemporal dementia, Parkinson's disease, Huntington's disease, prion-caused diseases and amyotrophic lateral sclerosis; chronic obstructive pulmonal diseases (COPD); prostata carcinoma and other tumors as well as metastases; Heavy Acute Respiratory Syndrome (SARS); and sepsis and sepsis-like conditions in a subject in need thereof, wherein the method comprises administering to the subject the composition of claim 118 in an amount sufficient for preventing or treating the at least one condition.

P29679.A06

132. (new) A method of preventing or treating at least one condition selected from atherosclerosis, arterial inflammation, reperfusion syndrome and stent restenosis in a subject in need thereof, wherein the method comprises administering to the subject the composition of claim 118 in an amount sufficient for preventing or treating the at least one condition.

133. (new) The method of claim 132, wherein the method comprises administering the composition by using a stent which is coated with the at least one of a composition and an active ingredient thereof.

134. (new) A stent which is coated with a composition of claim 118.

135. (new) A method of preventing or treating an inflammation reaction at, or caused by, a medical device implanted into an organism, wherein the method comprises administering to the organism the composition of claim 118 in an amount sufficient for preventing or treating the inflammation reaction.

136. (new) The method of claim 135, wherein the method comprises administering the composition at least one of as a coating or layer on the medical device and incorporated in the medical device.

P29679.A06

137. (new) The method of claim 135, wherein the method comprises administering the composition by at least one of a local and a systemic administration successively or concurrently.